PatentAug 10, 2026, 08:21 AM
Silo Pharma Secures European Patent for PTSD Treatment SPC-15
AI Summary
Silo Pharma announced that the European Patent Office (EPO) granted a patent for its lead candidate SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD) and stress-induced affective disorders. This patent, EP3952852, covers methods of preventing stress-induced fear and depressive-like behavior by administering serotonin 4 receptor agonists before stress exposure. The company holds an exclusive license for this European patent from Columbia University, further strengthening its global intellectual property for this novel preventative approach.
Key Highlights
- European Patent Office (EPO) granted a patent for Silo Pharma's lead candidate SPC-15.
- The patent, European Patent No. EP3952852, covers a preventative approach for stress-induced psychiatric disorders.
- SPC-15 is an intranasal, nose-to-brain treatment targeting PTSD and stress-induced affective disorders.
- The patent covers methods using serotonin 4 receptor agonists to prevent stress-induced fear and depressive-like behavior.
- Silo Pharma holds an exclusive license for the European patent from Columbia University.
- This expands the intellectual property portfolio for SPC-15, complementing protection in five other global markets.
Price Impact
More from SILO